These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 31658991)

  • 1. Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients.
    Ezekian B; Schroder PM; Mulvihill MS; Barbas A; Collins B; Freischlag K; Yoon J; Yi JS; Smith F; Olaso D; Saccoccio FM; Permar S; Farris AB; Kwun J; Knechtle SJ
    J Am Soc Nephrol; 2019 Dec; 30(12):2399-2411. PubMed ID: 31658991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belatacept-Based Maintenance Immunosuppression Controls the Post-Transplant Humoral Immune Response in Highly Sensitized Nonhuman Primates.
    Schmitz R; Fitch ZW; Manook M; Schroder PM; Choi AY; Olaso D; Yoon J; Bae Y; Shaw BI; Song M; Kuchibhatla M; Farris AB; Kirk A; Kwun J; Knechtle SJ
    Kidney360; 2022 Dec; 3(12):2116-2130. PubMed ID: 36591367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual targeting: Combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients.
    Burghuber CK; Manook M; Ezekian B; Gibby AC; Leopardi FV; Song M; Jenks J; Saccoccio F; Permar S; Farris AB; Iwakoshi NN; Kwun J; Knechtle SJ
    Am J Transplant; 2019 Mar; 19(3):724-736. PubMed ID: 30102844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model.
    Schroder PM; Schmitz R; Fitch ZW; Ezekian B; Yoon J; Choi AY; Manook M; Barbas A; Leopardi F; Song M; Farris AB; Collins B; Kwun J; Knechtle SJ
    Kidney Int; 2021 Jan; 99(1):161-172. PubMed ID: 32898569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection.
    Kim EJ; Kwun J; Gibby AC; Hong JJ; Farris AB; Iwakoshi NN; Villinger F; Kirk AD; Knechtle SJ
    Am J Transplant; 2014 Jan; 14(1):59-69. PubMed ID: 24354871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desensitization and belatacept-based maintenance therapy in pregnancy-sensitized monkeys receiving a kidney transplant.
    Manook M; Olaso D; Anwar IJ; Yoon J; Delaura I; Bae Y; Moris D; Shaw B; Song M; Farris AB; Jackson A; Kwun J; Knechtle S
    Sci Adv; 2023 May; 9(20):eadg1448. PubMed ID: 37205758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of interleukin-6 receptor blockade to carfilzomib-based desensitization in a highly sensitized nonhuman primate model.
    Anwar IJ; Ezekian B; DeLaura I; Manook M; Schroder P; Yoon J; Curfman V; Branum E; Messina J; Harnois M; Permar SR; Farris AB; Kwun J; Knechtle SJ
    Am J Transplant; 2022 Dec; 22 Suppl 4(Suppl 4):1-11. PubMed ID: 36239200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, iterative, adaptive trial of carfilzomib-based desensitization.
    Tremblay S; Driscoll JJ; Rike-Shields A; Hildeman DA; Alloway RR; Girnita AL; Brailey PA; Woodle ES
    Am J Transplant; 2020 Feb; 20(2):411-421. PubMed ID: 31550069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Mediated Rejection in Sensitized Nonhuman Primates: Modeling Human Biology.
    Burghuber CK; Kwun J; Page EJ; Manook M; Gibby AC; Leopardi FV; Song M; Farris AB; Hong JJ; Villinger F; Adams AB; Iwakoshi NN; Knechtle SJ
    Am J Transplant; 2016 Jun; 16(6):1726-38. PubMed ID: 26705099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Belatacept and carfilzomib-based treatment for antibody-mediated rejection in a sensitized nonhuman primate kidney transplantation model.
    Schmitz R; Manook M; Fitch Z; Anwar I; DeLaura I; Olaso D; Choi A; Yoon J; Bae Y; Song M; Farris AB; Kwun J; Knechtle S
    Front Transplant; 2023; 2():1230393. PubMed ID: 38993898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization.
    Choi AY; Manook M; Olaso D; Ezekian B; Park J; Freischlag K; Jackson A; Knechtle S; Kwun J
    Front Immunol; 2021; 12():694763. PubMed ID: 34177960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use.
    Kwun J; Matignon M; Manook M; Guendouz S; Audard V; Kheav D; Poullot E; Gautreau C; Ezekian B; Bodez D; Damy T; Faivre L; Menouche D; Yoon J; Park J; Belhadj K; Chen D; Bilewski AM; Yi JS; Collins B; Stegall M; Farris AB; Knechtle S; Grimbert P
    J Am Soc Nephrol; 2019 Jul; 30(7):1206-1219. PubMed ID: 31227636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition.
    Alishetti S; Farr M; Jennings D; Serban G; Uriel N; Sayer G; Vasilescu R; Restaino S; Chong AS; Habal MV
    Am J Transplant; 2020 Dec; 20(12):3620-3630. PubMed ID: 32506824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful desensitization with proteasome inhibition and costimulation blockade in sensitized nonhuman primates.
    Kwun J; Burghuber C; Manook M; Ezekian B; Park J; Yoon J; Yi JS; Iwakoshi N; Gibby A; Hong JJ; Farris AB; Kirk AD; Knechtle SJ
    Blood Adv; 2017 Nov; 1(24):2115-2119. PubMed ID: 29296858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costimulatory blockade molecules and B-cell-mediated immune response: current knowledge and perspectives.
    Leibler C; Thiolat A; Elsner RA; El Karoui K; Samson C; Grimbert P
    Kidney Int; 2019 Apr; 95(4):774-786. PubMed ID: 30711200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary lymphoid tissue and costimulation-blockade resistant rejection: A nonhuman primate renal transplant study.
    Mulvihill MS; Samy KP; Gao QA; Schmitz R; Davis RP; Ezekian B; Leopardi F; Song M; How T; Williams K; Barbas A; Collins B; Kirk AD
    Am J Transplant; 2019 Aug; 19(8):2350-2357. PubMed ID: 30891931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of Tfh:B Cell Interactions Prevents Antibody-Mediated Rejection in a Kidney Transplant Model in Rats: Impact of Calcineurin Inhibitor Dose.
    Steines L; Poth H; Schuster A; Amann K; Banas B; Bergler T
    Front Immunol; 2021; 12():657894. PubMed ID: 34135891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation.
    Guthoff M; Schmid-Horch B; Weisel KC; Häring HU; Königsrainer A; Heyne N
    Transpl Immunol; 2012 Jun; 26(4):171-5. PubMed ID: 22326708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of combined plasma cell therapy and costimulation blockade based desensitization regimen in heart transplant candidates.
    Fida N; Eagar TN; Yun AN; Rogers AW; Nguyen DT; Graviss EA; Ishaq F; DiPaola NR; Kim J; Janardhana G; Kassi M; Yousefzai R; Suarez EE; Bhimaraj A; Krisl JC; Guha A
    Clin Transplant; 2024 Feb; 38(2):e15249. PubMed ID: 38369810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model.
    Reese SR; Wilson NA; Huang G; Redfield RR; Zhong W; Djamali A
    Transplantation; 2015 Sep; 99(9):1785-95. PubMed ID: 25919767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.